Rola dopelniacza w odpornosci na zakazenia pierwotniakami

• Autorzy: Jankowski S
• Języki publikacji: PL

Abstrakty

EN

The scope of this work is the presentation of new theories concerning the role of complement (C) in the resistance of high organism to the infection caused by protozoa. The mechanisms protecting of Entamoeba histolytica, Leishmania spp., Trypanosoma cruzi, Toxoplasma gondii and Naegleria fowleri from the action of C are also described.

Słowa kluczowe

PL

Naegleria fowleri; dopelniacze; odpornosc organizmow; bialko C; swidrowce; Toxoplasma gondii; mechanizmy obronne; Leishmania; opornosc na pasozyty; parazytologia; pierwotniaki; inwazja pasozytnicza; Trypanosoma cruzi; Entamoeba histolytica

• Wydawca: -
• Czasopismo: Wiadomości Parazytologiczne
• Rocznik: 1997
• Tom: 43
• Numer: 4
• Opis fizyczny: s.369-383, rys.,tab.,bibliogr.

Twórcy

autor

Jankowski S

• Akademia Medyczna, ul.Mikulicza-Radeckiego 9, 50-368 Wroclaw

Bibliografia

• ALMEIDA I. C., MILANI S. R., GORIN P. A., TRAVASSOS L. R. 1991. Complement mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-α-galactosyl antibodies. J. Immunol. 146: 2394-2400.
• BLAKELEY P., SARGEAUNT P. G., REED S. L. 1990. An immunogenic 30-kDa surface antigen of pathogenic clinical isolates of Entamoeba histolytica. J. Infect. Dis. 162: 949-954.
• BRAGA L. L., NINOMIYA H., MCCOY J. J. 1992. Inhibition of the complement membrane attack complex by the galactose-specific adhesin of Entamoeba histolytica. J. Clin. Invest. 90: 1131-1137.
• BRITTINGHAM A., MORRISON C. J., MCMASTER W. R., MCGWIRE B. R., CHANG K. P., MOSSER D. M. 1995. Role of the Leishmania surface protease gp63 in complement fixation, cell adhesion and resistance to complement-mediated lysis. J. Immunol. 155: 3102-3111.
• - MOSSER D. M. 1996. Exploitation of the complement system by Leishmania promastigotes. Parasitol. Today 12: 444-447.
• CALDERON J., SOIREIBER R. D. 1985. Activation of the alternative and classical complement pathways by Entamoeba histolytica. Infect. Immun. 50: 560-565.
• CARROLL M. C., FISCHER M. B. 1997. Complement and the immune response. Current Opinion Immunol. 9: 64-69.
• DENSEN P. 1989. Interaction of complement with Neisseria meningitidis and Neisseria gonorrhoeae. Clin. Microbiol. Rev. 2: S11-S17.
• FISCHER E., OUAISSI M. A., VEWE P., CORNETIE J., KAZATCHKINE M. D. 1988. Gp58/68, a parasite component that contributes to the escape of the trypomastigote form of T. cruzi from damage by the human alternative complement pathway. Immunology 65: 299-303.
• FISHELSON Z. 1994. Complement-related proteins in pathogenic organisms. Spring. Semin. Immunopathol. 15: 345-368.
• FRANKE E. D., MCGREEVY P. B., KATZ S. P., SACKS D. L. 1985. Growth cycle-dependent generation of complement-resistant Leishmania promastigotes. J. Immunol. 134: 2713-2718.
• FUHRMAN S. A., JOINER K. A. 1989. Toxoplasma gondii: mechanism of resistance to complement-mediated killing. Ibid. 142: 940-947.
• GAZZINELLI R. T., PERIERA M. E., ROMANHA A., GAZZINELLI G., BRENER Z. 1991. Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunol. 13: 345-356.
• HAMELMANN C., FOERSTER B., BURCHARD G. D., HORSTMANN R. D. 1992. Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement methodological analysis. Ibid. 14: 23-25.
• - - - SHETTY N., HORSTMANN R. D. 1993a. Induction of complement resistance in cloned pathogenic Entamoeba histolytica. Ibid. 15: 223-228.
• - URBAN B., FOERSTER B., HORSTMANN R. D. 1993b. Complement resistance of pathogenic Entamoeba histolytica mediated by trypsin-sensitive surface component(s). Infect. Immun. 61: 1636-1640.
• HERMOSO T., FISHELSON Z., BECKERS. J., HIRSCHBERG K., JAFFE C. L. 1991. Leishmanial protein kinases phosphorylate components of the complement system. EMBO J. 10: 4061-4067.
• IIDA K., WHITLOW M. B., NUSSENZWEIG V. 1989. Amastigotes of Trypanosoma cruzi escape destruction by the terminal complement components. J. Exp. Med. 169: 881-891.
• IKEDA K., SANNOH T., KAWASAKI N., YAMASHINA I. 1987. Serum lectin with known structure activates complement through the classical pathway. J. Biol. Chem. 262: 7451-7454.
• JANKOWSKI S. 1995. Mechanizmy obronne chroniące bakterie Gram-ujemne przed bakteriobójczym działaniem dopełniacza. Post. Mikrobiol. 34: 23-44.
• - 1997. Właściwości biologiczne komplementu. II Konferencja Naukowa „Zaburzenia odporności wieku rozwojowego". Wrocław, 24-25.04.1997. Materiały Naukowe: 7-15.
• - GALAR A., GRZYBEK-HRYNCEWICZ K., WALCZUK M. 1991. Bactericidal activity of serum of a child with focal proliferative glomerulonephritis. Nephron. 58: 491.
• - GRZYBEK-HRYNCEWICZ K. 1995. Znaczenie bakteriobójczego działania dopełniacza w odporności na zakażenia bakteriami Gram-ujemnymi. Post. Med. Klin. Dośw. 4: 479-490.
• JOINER K. A., DA SILVA DIAS W., RIMOLDI M. T., HAMMER C. H., SHER A., KIPNIS T. L. 1988. Biochemical characterization of a factor produced by trypomastigotes of Trypanosoma cruzi that accelerates the decay of complement C3 convertases. J. Biol. Chem. 263: 11237-11240.
• JOKIRANTA T. S., JOKIPII L., MERI S. 1995. Complement resistance of parasites. Scand. J. Immunol. 42: 9-20.
• KAWASAKI N., KAWASAKI T., YAMASHINA I. 1989. A serum lectin (mannan-binding protein) has complement-dependent bactericidal activity. J. Biochem. 106: 483-489.
• KEMP M. 1997. Regulator and effector functions of T-cell subsets in human Leishmania infections. AMPIS 105: 3-33.
• KIPNIS T. L., DA SILVA DIAS W. 1989. Evasion of Trypanosoma cruzi from complement lysis. Brazilian. J. Med. Biol. Res. 22: 1-16.
• - DAVID J. R., ALPER C. A., DA SILVA DIAS W. 1981. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc. Nat. Acad. Sci. USA. 78: 602-605.
• - KRETILI A. U., DA SILVA DIAS W. 1985. Transformation of trypomastigote bloodstream forms of Trypanosoma cruzi into activators of the alternative complement pathway by immune IgG fragments. Scand. J. Immunol. 22: 217-226.
• KOZEL T. R. 1996. Activation of the complement system by pathogenicfungi. Clin. Microbiol. Rev. 9: 34-46.
• KUHLMAN M., JOINER K. A., EZEKOWITZ R. A. B. 1989. The human mannose-binding protein functions as an opsonin. J. Exp. Med. 169: 1733-1745.
• LAW S. K. A., DODDS A. W. 1997. The internal thioester and the covalent binding properties of the complement proteins C3 and C4. Protein Sci. 6: 263-274.
• MARCIANO-CABRAL F ., TONEY D. M. 1994. Modulation of biological functions of Naegleria fowleri amoebae by growth medium J. Eukaryot. Microbiol. 41: 38-46.
• MARSCHANG P., EBENBICHLER C. F., DIERICH M. P. 1994. HIV and complement: role of the complement system in HIV infection. Int. Arch. Allergy Immunol. 103: 113-117.
• MATSUSMTA M., FUJITA T. 1992. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J. Exp. Med. 176: 1497-1502.
• MCCOY J. J., MANN B. J ., VEDVIC T. S., PAK Y., HEIMARK D. B., PETRI W. 1993. Structural analysis of the light subunit of the Entamoeba histolytica galactose-specific adherence lectin. J. Biol. Chem. 268: 24223-24231.
• MERI S., PANGBURN M. K. 1990. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. USA 87: 3982-3985.
• MOGYOROS M., CALEF C., GITLER C. 1986. Virulence of Entamoeba histolytica correlates with thecapacity to develop complement resistance. Isr. J. Med. Sci. 22: 915-917.
• MORGAN B. P., VORA J. P., BENNETT A. J., THOMAS J. P., MATTHEWS N. 1989. A case of hereditary combined deficiency of complement components C6 and C7 in man. Clin. Exp. Immunol. 75: 396-401.
• MOSSER D. M., BURKE S. K., COUTAVAS E. E., WEDGWOOD J. F ., EDELSON P. J. 1986. Leishmania species: mechanism of complement activation by live strains of promastigotes. Exp. Parasitol. 62: 394-398.
• - EDELSON P. J. 1984. Activation of the alternative complement pathway by Leishmania promastigotes: parasite lysis and attachment to macrophages. J. Immunol. 132: 1501-1505.
• - - 1987. The third component of complement (C3) is responsible for the intracellular survival of Leishmania major. Nature 327: 329-331.
• - SPRINGER T. A., DIAMOND M. S. 1992. Leishmania promastigotes require opsonic complement to bind to the human leukocyte integrin Mac-1 (CD11b/CD18). J. Cell Biol. 116: 511-520.
• MUKHERJEE R. M., BHOL K. C., MEHRA S., MAITRA T. K., JALAN K. N . 1992. High cell surface hydrophobicity of virulent Entamoeba histolytica isolates. Trans. R. Soc. Trop. Med. Hyg. 86: 396-398.
• MÜLLER-EBERHARD H. J. 1992. Complement chemistry and pathways. In: I. L. Gallin, L. Goldstein and M. Snyderman (Eds), Inflamation: Basic Principles and Clinical correlates. New York, Raven Press: 33-61.
• NAKAO M., KONISHI E. 1991. Proliferation of Toxoplasma gondii in human neutrophils in vitro. Parasitology 1: 23-27.
• NORRIS A. K. 1996. Ligand-binding renders the 160 kDa Trypanosoma cruzi complement regulatory protein susceptible to proteolytic cleavage. Microbial Pathogen. 21: 235-248.
• - BRADT B., COOPER N ., SO M. 1991. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the complement regulatory protein, decay accelerating factor. J. Immunol. 147: 2240-2247.
• - SCHRIMF J. 1994. Biochemical analysis of the membrane and soluble forms of the complement regulatory forms of the complement regulatory protein of Trypanosoma cruzi. Infect. Immun.62: 236-243.
• PANGBURN M. K., MÜLLER-EBERHARD H. J. 1980. Relation to a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 152: 1102-1105.
• PEARSON R. T., STEIGBIGEL R. T. 1980. Mechanism of lethal elfect of human serum upon Leishmania donovani. J. Immunol. 125: 2195-2201.
• PODACK E. R. 1986. Molecular mechanisms of cytolysis by complement and by cytolytic lymphocytes. J. Cel. Biochem. 30: 133-164.
• PUENTES S. M., DA SILVA R. P., SACKS D. L., HAMMER C. H., JOINER K. A. 1990. Serum resistance of metacyclic stage Leishmania major promastigotes in due to release of C5b-9. J. Immunol. 145: 4311-4316.
• - DWYER D. M., BATES P . A., JOINER K. A. 1989. Binding and release of C3 from Leishmania donovani promastigotes during incubation in normal human serum. Ibid. 143: 3743-3749.
• - SACKS D. L., DA SILVA R. P., JOINER K. A. 1988. Complement binding by two development stages of Leishmania major promastigotes varying in expression a surface lipophosphoglycan. J. Exp. Med. 167: 887-902.
• REED S. L., CURD J. G., GIGLI I., GILLIN F. D., BRAUDE A. I. 1986. Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica. J. Immunol. 136: 2265-2270.
• - SARGEAUNT P. G., BRAUDE A. I. 1983. Resistance to lysis by human serum of pathogenic Entamoeba histolytica. Trans. R. Soc. Trop. Med. Hyg. 77: 248-250.
• ROORD J. J., DAHA M., KUIS W., VERBRUGH I., VERHOEF J., ZEGERS B. J., STOOL J. W. 1983. Inherited deficiency of the third component of complement associated with recurrent pyogenic infections, circulating immune complexes and vasculitis in dutch family. Pediatrics 71: 81-87.
• RUSSELL D. G. 1987. The macrophage-attachment glycoprotein gp63 is the predominant C3-acceptor site on Leishmania mexicana promastigotes. Eur. J. Biochem. 164: 213-221.
• SACKS D. L., BRODIN T. N ., TURCO S. J. 1990. Developmental modification of the lipophosphoglycan from Leishmania major promastigotes during metacyclogenesis. Mol. Biochem. Parasitol. 42: 225-233.
• SANTOS-GOMES G. M., ABRANCHES P. 1996. Comparative study of infectivity caused by promastigotes of Leishmania infanatum MON-1, L. infanatum MON-24 and L. donovani MON-18. Folia Parasitol. 43: 7-12.
• SHER A., HIENY S., JOINER K. A. 1986. Evasion of the alternative complement pathway by mtacyclic trypomastigotes of Trypanosoma cruzi: dependence on the developmentally regulated synthesis of surface protein and N-linked carbohydrate. J. Immunol. 137: 2961-2965.
• SOLBACH W., LASKY T. 1996. Evasion strategies of Leishmania parasites. In: F. J. Tapia, G. Caceres-Dittmar and M. A. Sanchez (Eds.), Molecular and Immune Mechanisms in the Pathogenesis of Cutaneous Leishmaniasis. R. G. Landes Company: 25-47.
• THIEL S., VORUP-JENSEN T., STOVER C. M., SCHWAEBLE W., LAURSEN S. B., POULSEN K., WILLIS A. C., EGGLETON P., HANSEN S., HOLMSKOV U., REID K. M., JENSENIUS J. C. 1997. A second serine protease associated with mannan-binding lectin that activates complement. Nature 386: 506-510.
• TOMLINSON S., PONTES DE CARVALAHO L. C., VANDEKERCKHOVE F., NUSSENZWEIG V. 1994. Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. J. Immunol. 153: 3141-3147.
• TONEY D. M., MARCIANO-CABRAL F. 1992. Alterations in protein expresion and complement resistance of pathogenic Naegleria amoebae. Infect. Immun. 60: 2784-2790.
• - - 1994. Membrane vesiculation of Naegleria fowleri amoebae as a mechanism for resisting complement damage. J. Immunol. 152: 2952-2959.
• TURNER M. 1996. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today 17: 532-540.
• URBAN B., BLASIG C., FORSTER B., HAMELMANN C., HORSTMANN R. D. 1996. Putative serine/threonine kinase expressed in complement-resistant forms of Entamoeba histolytica. Mol. Biochem. Parasitol. 80: 171-178.
• WHITEMAN L. Y., MARCIANO-CABRAL F. 1989. Resistance of highly pathogenic Naegleria fowleri amoebae to complement-mediated lysis. Infect. Immun. 57: 3869-3875.